Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy.
10.3904/kjm.2016.90.3.210
- Author:
Hyoung Seob PARK
1
Author Information
1. Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. drparkgyver@gmail.com
- Publication Type:Review
- Keywords:
Defibrillators, Implantable;
Cardiac resynchronization therapy;
Heart failure
- MeSH:
Arrhythmias, Cardiac;
Cardiac Resynchronization Therapy*;
Death, Sudden, Cardiac;
Defibrillators, Implantable*;
Heart Arrest;
Heart Failure;
Hospitalization;
Humans;
Primary Prevention;
Tachycardia
- From:Korean Journal of Medicine
2016;90(3):210-216
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The use of an implantable cardioverter-defibrillator (ICD) is an effective treatment strategy for patients with aborted sudden cardiac death (SCD) and ventricular tachyarrhythmias. Primary prevention of SCD is a strategy involving the use of ICDs in patients who are at high risk for but who have not had any previous events of ventricular arrhythmias or cardiac arrest. Cardiac resynchronization therapy (CRT) improves symptoms of heart failure and left ventricular systolic function when used in patients with severe heart failure symptoms, reduced left ventricular ejection, and a wide QRS complex. CRT has also been proven to reduce the rate of hospitalization due to heart failure as well as the rate of death from any cause. In this review, we discuss the clinical trials and current clinical indications for the ICD and CRT.
